DE

Urgent Notice of the Federal Patent Court: Preliminary Injunction issued in a Compulsory License Proceedings concerning “Isentress” (raltegravir against AIDS)

This is in follow up to our IP newsletter of September 1, 2016. The German Federal Patent Court now issued an urgent notice with the following content:

  • In compulsory license proceedings, regarding the question whether the license seeker has made unsuccessful efforts to obtain authorization for use of the invention on reasonable commercial terms and conditions (Sec. 24 Para. 1 No. 1 Patents Act), the primary focus has to be put on the perspective of the license seeker. It is only required by him to make attempts to obtain a license on conditions that a reasonable, economically thinking third party would be willing to accept in this situation, allowing room for certain negotiations – under the reservation that such efforts are not feigned. Thereby, he could consider circumstances, which challenge the validity of the respective patent from his point of view.

  • The offer of the license seeker need not meet the requirements of a compulsory license under anti-trust laws or the anti-trust objection of compulsory license.

  • Next to the urgency in the meaning of Sec. 85 Para. 1 Patents Act, the procedural urgency (in the meaning of Secs. 935, 940 ZPO – German Code of Civil Procedure) is not an additional requirement for the grant of a preliminary injunction under Sec. 85 Para. 1 Patents Act.

The complete decision is already published in BeckRS 2016, 113453. An English translation will follow soon. Our Munich partner, Fritz Lahrtz who is one of the leaders of the litigation team representing the proprietor of the patent, would be happy to give you more detailed information about the decision.

More articles from Dr. Ulrike Herr

SPCs for combination products – The CJEU sets out the criteria for combinations of active ingredients being “protected by a basic patent”

Dr. Ulrike Herr

We are pleased to announce that our Munich partner Dr. Ulrike Herr was reelected today as a member of the Board of the German Chamber of Patent Attorneys

Dr. Ulrike Herr

Preliminary Injunctions rejected in Infringement Proceedings concerning Gilead’s SPC Supplementary Protection Certificate of the anti-HIV drug Truvada in Germany

Dr. Ulrike Herr

Highly Topical: Supplementary Protection Certificates SPCs in Europe – Seattle Genetics Decision (C-471/14) of the CJEU of October 6, 2015 – Good news for SPC Owners

Dr. Ulrike Herr

Urgent Notice of the Federal Patent Court: Preliminary Injunction issued in a Compulsory License Proceedings concerning “Isentress” (raltegravir against AIDS)

Dr. Ulrike Herr

SPCs and Medical Devices: Regulation 469/2009 requires a pharmacological, immunological or metabolic action of the product of its own: BPatG Decision 14 W (pat) 45/12

Dr. Ulrike Herr

Highly Topical: SPCs Supplementary Protection Certificates in Europe – Seattle Genetics Decision (C-471/14) of the CJEU of October 6, 2015 – Good news for SPC Owners

Dr. Ulrike Herr

Reference to an ISO Standard Renders a Claim Unclear under the EPC

Dr. Ulrike Herr

The article “BPatG – Telmisartan. Zur Nichtigkeit von ergänzenden Schutzzertifikaten für Wirkstoffkombinationen” by Ulrike Herr was published in IP kompakt

Dr. Ulrike Herr

Supplementary Protection Certificates – Three post-Medeva Decisions of the CJEU of Dec 12, 2013

Dr. Ulrike Herr

SPC Case Law - Astrazeneca AB/Comptroller-General of Patents C-617/12 of Nov. 14, 2013 (Reasoned order)

Dr. Ulrike Herr